CLINICAL STUDY

Differential gene expression in ACTH -secreting and non-functioning pituitary tumors

Toru Tateno, Hajime Izumiyama, Masaru Doi, Takanobu Yoshimoto, Masayoshi Shichiri, Naoko Inoshita, Kenichi Oyama, Shozo Yamada and Yukio Hirata

Department of Clinical and Molecular Endocrinology, Tokyo Medical and Dental University Graduate School, 1-5-45, Yushima, Bunkyo-ku, Tokyo, Japan, Departments of Pathology and Hypothalamic and Pituitary Surgery, Toranomon Hospital, Tokyo, Japan

(Correspondence should be addressed to T Tateno; Email: ttateno.cme@tmd.ac.jp)

Abstract

Objective: Differential expression of several genes between ACTH-secreting pituitary tumors causing Cushing’s disease (CD), silent corticotroph adenoma (SCA), and non-functioning pituitary tumors (NFT) was investigated.

Design and methods: We used tissue specimens from 35 pituitary tumors (12 CD, 8 SCA, and 15 NFT). Steady-state mRNA levels of the genes related to proopiomelanocortin (POMC) transcription, synthesis, processing, and secretion, such as neurogenic differentiation 1 (NeuroD1), T-box 19 (Tpit), corticotropin releasing hormone receptor (CRHR), vasopressin receptor 1b (V1bR), prohormone convertase (PC) 1/3 and PC2, 11β-hydroxysteroid dehydrogenase (11β-HSD) type 1 and type 2, glucocorticoid receptor α (GRα), annexin A1, histone deacetylase 2 (HDAC2), and BRM/SWI2-related gene 1, were determined by real-time RT-PCR.

Results and conclusion: POMC and Tpit mRNA levels were greater in CD and SCA than those in NFT. NeuroD1 mRNA levels were less in CD than those in NFT, but almost comparable between SCA and NFT. PC1/3 mRNA levels were greater in CD, but less in SCA than those in NFT. PC2 mRNA levels in CD and SCA were less than those in NFT. CRHR, V1bR, and 11β-HSD2 mRNA levels in CD were greater than those in SCA and NFT. HDAC2 mRNA levels in CD and SCA were lower than those in NFT. In conclusion, our study demonstrated that the genes related to transcription, synthesis, processing, and secretion of POMC are differentially regulated in ACTH-secreting pituitary tumors causing CD and SCA compared with those in NFT. This may partly explain the development of clinically active and inactive CD.

Introduction

In adrenocorticotropic (ACTH)-secreting pituitary tumors causing Cushing’s disease (CD), hypercortisolemia induces a diversity of clinical manifestations, including moon face, central obesity, diabetes, hypertension, osteoporosis, and so on. By contrast, silent corticotroph adenoma (SCA) is defined as a pituitary adenoma with positive immunoreactivity for ACTH without any signs and symptoms of Cushing’s syndrome (1). In SCA, plasma ACTH levels are usually normal (2). Neither the mechanism(s) for the dysregulation of ACTH secretion in ACTH-secreting pituitary tumors nor the mechanism(s) accounting for the lack of Cushingoid features in SCA are fully understood.

Possible differential expression of a variety of genes related to proopiomelanocortin (POMC) transcription, synthesis, processing, transport, and secretion between ACTH-secreting pituitary tumors and non-functioning pituitary tumors (NFT) could be postulated. Two previous studies using DNA microarrays revealed that a limited number of genes related to tumorigenesis are differentially expressed in pituitary tumors (3, 4). However, to the best of our knowledge, the expression profile of the genes related to POMC transcription, synthesis, processing, secretion, and intracellular trafficking in ACTH-secreting pituitary tumors and NFT have not been extensively studied to date. Therefore, the present study was designed to investigate the expression profile of a variety of such genes in tumor tissues obtained from surgery using a quantitative reverse transcriptase-PCR (RT-PCR) technique.

Patients and methods

Patients

Thirty-five patients (13 male and 22 female, mean age 47.8 ± 2.6 years old), who underwent transphenoidal surgery for removal of pituitary tumors at the Department of Hypothalamic and Pituitary Surgery, Toranomon Hospital, were studied. Informed consent was obtained from each patient before surgery. Based on clinical,
endocrinological, and immunohistochemical study. 12 were diagnosed as CD, 8 as SCA, and 15 as NFT. The diagnosis of CD was made based on signs and symptoms of Cushing’s syndrome, endocrine data (increased plasma ACTH and serum cortisol concentrations, lack of diurnal rhythm, suppression after high-dose (8 mg) dexamethasone, and/or hyperresponse of ACTH to corticotropin releasing hormone, CRH), and the presence of a pituitary tumor by diagnostic magnetic resonance image, which was confirmed by the demonstration of positive immunoreactivity for ACTH in pituitary tumor cells. The diagnosis of SCA was based on positive immunoreactivity for ACTH in pituitary tumor cells without any signs or symptoms of Cushing’s syndrome.

The female-to-male ratio of ACTH-secreting tumors (CD and SCA) was greater (P < 0.01) than that in NFT. Patients with CD (38.6 ± 4.6 years old) were significantly (P < 0.05) younger than those with SCA (52.1 ± 3.4 years old) and NFT (52.9 ± 4.6 years old). The tumor sizes in CD (11.8 ± 2.2 mm) were significantly (P < 0.05) smaller than those in SCA (42.8 ± 12.2 mm) and NFT (30.2 ± 2.0 mm). Both plasma ACTH levels (172.2 ± 30.6 pg/ml) and serum cortisol levels (33.5 ± 4.8 µg/dl) in CD were significantly (P < 0.01) higher than those in SCA (ACTH 29.9 ± 4.5 pg/ml, cortisol 9.9 ± 1.6 µg/dl) and NFT (ACTH 29.9 ± 5.3 pg/ml, cortisol 13.4 ± 1.4 µg/dl) respectively.

**Preparation of tissue specimens**

Tissue specimens were obtained during transphenoidal surgery from each pituitary tumor. A portion of the surgical tissue specimens was immediately frozen with RNAlater (Ambion Inc., Austin, TX, USA) in liquid nitrogen and stored at −80 °C. The remaining tissue specimens were subjected to histological and immunohistochemical studies.

**Quantification of mRNA**

Total RNA was extracted from pituitary tumors (30–200 mg) using the TRizol reagent protocol (Life Technologies Inc). Five micrograms total RNA were reverse transcribed with a first-strand synthesis kit (GE Healthcare, Chalfont, Buckinghamshire, UK). mRNA levels of POMC, neurogenic differentiation 1 (NeuroD1), T-box 19 (Tpit), CRH receptor (CRHR), vasopressin receptor 1b (V1bR), prohormone convertase (PC)1/3, PC2, 11β-hydroxysteroid dehydrogenase 1 and -2 (11β-HSD1, -2), glucocorticoid receptor z (GRz), annexin A1 (ANXA1), histone deacetylase 2 (HDAC2), BRM/SWI2-related gene 1 (Brg1), Ras-associated protein 3 (Rab3), syntaxin6, and membrane associated ring finger protein 2 (MARCH2), were quantified with real-time RT-PCR using SYBR green real-time PCR method, fluorescence data were quantitatively analyzed using serial dilution of control samples included in each reaction to produce a standard curve. To compare the relative expression of each gene, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an endogenous internal control and the relative levels of each mRNA to that of GAPDH were calculated.

**Statistical analysis**

Data were expressed as means ± S.E.M. Differences between groups were examined for statistical significance using unpaired t-test or ANOVA with Dunn’s post hoc test, if they were appropriate. P values < 0.05 were considered statistically significant.

**Results**

**Expression profile of genes related to POMC and transcription factors**

We first quantified steady-state mRNA levels POMC and transcription factors (NeuroD1 and Tpit) in ACTH-secreting tumors (CD and SCA) and NFT (Fig. 1). POMC mRNA levels in CD and SCA were about 136-fold (P < 0.01) and 5-fold (P < 0.05) greater than those in NFT respectively. NeuroD1 mRNA levels in CD were less than those in SCA and NFT by about 45- to 65-fold (P < 0.05) respectively, whereas Tpit mRNA levels in CD and SCA were greater than those in NFT by about 26-fold (P < 0.01) and 13-fold (P < 0.05) respectively.

**Expression profile of genes related to secretion and processing of POMC and glucocorticoid-metabolizing enzymes**

Next we studied expression of genes related to regulation of ACTH secretion (CRHR and V1bR) in ACTH-secreting tumors (CD and SCA) and NFT (Fig. 2). CRHR mRNA levels in CD were greater than those in SCA and NFT by about 376- and 13-fold respectively (P < 0.01), while V1bR mRNA levels in CD and SCA were about 15- and 5-fold greater than those in NFT respectively (P < 0.01).

We then determined expression of genes related to POMC processing enzymes (PC1/3 and PC2) in ACTH-secreting tumors (CD and SCA) and NFT (Fig. 3a and b). PC1/3 mRNA levels were about threefold greater in CD (P < 0.01), but about fivefold lower in SCA (P < 0.05) than those in NFT respectively. By contrast, PC2 mRNA levels in CD and SCA were far less than those in NFT by 33- and 100-fold respectively (P < 0.05).

mRNA levels of 11β-HSD2 in CD, but not in SCA, were about fivefold greater than those in NFT (P < 0.05), whereas 11β-HSD1 mRNA levels did not differ among the three tumor groups (Fig. 3c and d).
Expression profile of genes related to negative feedback of POMC by glucocorticoid

Since abnormal negative feedback of POMC by glucocorticoid is the hallmark of CD, we investigated the expression profile of several genes related to negative feedback regulation by glucocorticoids (GRα, ANXA1, HDAC2, and Brg1) in ACTH-secreting tumors (CD and SCA) and NFT (Fig. 4). GRα mRNA levels did not differ among the three tumor groups, while ANXA1 mRNA levels were comparable between CD and SCA, but highly variable in NFT. HDAC2 mRNA levels in CD and SCA were

<table>
<thead>
<tr>
<th>Primers</th>
<th>Sequences</th>
<th>PCR product size (bp)</th>
</tr>
</thead>
<tbody>
<tr>
<td>POMC</td>
<td>Forward: CTACGGCGGTTTTCATGACCT</td>
<td>98</td>
</tr>
<tr>
<td></td>
<td>Reverse: CCCTCACTGCCCTTCCTTG</td>
<td></td>
</tr>
<tr>
<td>NeuroD1</td>
<td>Forward: GCCCCAGGGTTAGGAGCTA</td>
<td>160</td>
</tr>
<tr>
<td></td>
<td>Reverse: GCTCCCTGCTCTGGAACAAGT</td>
<td></td>
</tr>
<tr>
<td>Tpit</td>
<td>Forward: CTGTGCGGAGGCTCTCTTG</td>
<td>167</td>
</tr>
<tr>
<td></td>
<td>Reverse: AGCGGCTACCTGTGAATTGG</td>
<td></td>
</tr>
<tr>
<td>CRHR</td>
<td>Forward: CTGCTGGGAGCATCTACCAT</td>
<td>116</td>
</tr>
<tr>
<td></td>
<td>Reverse: GACAAAGAAGCCCTTGGAA</td>
<td></td>
</tr>
<tr>
<td>V1bR</td>
<td>Forward: CAAGATCCCGAGACAGTGGAAGTG</td>
<td>148</td>
</tr>
<tr>
<td></td>
<td>Reverse: CATAGAGATGGTGAAAGCCACA</td>
<td></td>
</tr>
<tr>
<td>PC1/3</td>
<td>Forward: CGCTGACCTGCAACATGACT</td>
<td>140</td>
</tr>
<tr>
<td></td>
<td>Reverse: CGACACGGGTGGCTG</td>
<td></td>
</tr>
<tr>
<td>PC2</td>
<td>Forward: CGGTGGAGGCGCAAGAGAAG</td>
<td>101</td>
</tr>
<tr>
<td></td>
<td>Reverse: TTTCTGACCAACCAGGAGA</td>
<td></td>
</tr>
<tr>
<td>11β-HSD1</td>
<td>Forward: GAAGAACCCTCTCAAAGCAA</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>Reverse: GAGCAGTCAACACTTTCGA</td>
<td></td>
</tr>
<tr>
<td>11β-HSD2</td>
<td>Forward: GACCTGACCAACCAGGAGA</td>
<td>121</td>
</tr>
<tr>
<td></td>
<td>Reverse: CGCATCGCAAGACTCTTCA</td>
<td></td>
</tr>
<tr>
<td>GRα</td>
<td>Forward: GAAGAACCCTCTCAAAGCAA</td>
<td>151</td>
</tr>
<tr>
<td></td>
<td>Reverse: CATCTGCTCCCTTTCCTTCTC</td>
<td></td>
</tr>
<tr>
<td>ANXA1</td>
<td>Forward: GCTGAGGCTGAGGAGCTGA</td>
<td>104</td>
</tr>
<tr>
<td></td>
<td>Reverse: ACGTGTGTCCTCCTTTCCTT</td>
<td></td>
</tr>
<tr>
<td>HDAC2</td>
<td>Forward: CGATGGTGGAGGCTGGAAG</td>
<td>139</td>
</tr>
<tr>
<td></td>
<td>Reverse: AATTCAAGATGGCGACA</td>
<td></td>
</tr>
<tr>
<td>Brg1</td>
<td>Forward: AGGCAAATCCAGAAGCTGA</td>
<td>165</td>
</tr>
<tr>
<td></td>
<td>Reverse: CGCTTGTTCCTTCTGCTC</td>
<td></td>
</tr>
<tr>
<td>Rab3A</td>
<td>Forward: TGCTGGAATTTCTGGGGA</td>
<td>106</td>
</tr>
<tr>
<td></td>
<td>Reverse: GTCCACGGACAGCATCT</td>
<td></td>
</tr>
<tr>
<td>Syntaxin6</td>
<td>Forward: GACCCCTTCTTGTGGTGAAG</td>
<td>127</td>
</tr>
<tr>
<td></td>
<td>Reverse: TGGCTCAGTCTGGTTCTCC</td>
<td></td>
</tr>
<tr>
<td>MARCH2</td>
<td>Forward: CTCAGCCCTCCAGAAGCTG</td>
<td>124</td>
</tr>
<tr>
<td></td>
<td>Reverse: CCTAGGCCAGGAGTTTGAG</td>
<td></td>
</tr>
<tr>
<td>GAPDH</td>
<td>Forward: GCTGAGGACGGGAAGCTGT</td>
<td>136</td>
</tr>
<tr>
<td></td>
<td>Reverse: TCTCCATTGCTGGTGAG</td>
<td></td>
</tr>
</tbody>
</table>

POMC, proopiominocortin; NeuroD1, neurogenic differentiation 1; Tpit, T-box 19; CRHR, corticotropin releasing hormone receptor; V1bR, vasopressin receptor 1b; PC, prohormone convertase; 11β-HSD, 11β-hydroxysteroid dehydrogenase; GR, glucocorticoid receptor; ANXA1, annexin A1; HDAC2, histone deacetylase 2; Brg1, BRM/SWI2-related gene 1; Rab, Ras-associated protein; MARCH, membrane associated ring finger protein; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

Expression profile of genes related to negative feedback of POMC by glucocorticoid

Since abnormal negative feedback of POMC by glucocorticoid is the hallmark of CD, we investigated the expression profile of several genes related to negative feedback regulation by glucocorticoids (GRα, ANXA1, HDAC2, and Brg1) in ACTH-secreting tumors (CD and SCA) and NFT (Fig. 4). GRα mRNA levels did not differ among the three tumor groups, while ANXA1 mRNA levels were comparable between CD and SCA, but highly variable in NFT. HDAC2 mRNA levels in CD and SCA were

![Figure 1](https://www.eje-online.org) Figure 1 Expression profile of genes related to POMC and transcription factors (NeuroD1 and Tpit) in ACTH-secreting pituitary tumors (CD and SCA) and NFT. Steady-state mRNA levels of (a) POMC, (b) NeuroD1, and (c) Tpit as determined by real-time quantitative RT-PCR are shown. Data are expressed as fold increase over those of NFT (open column); each column is the mean; bar shows s.e.m. *P<0.01, **P<0.05.
significantly ($P < 0.05$) less than those in NFT by about tenfold, while Brg1 mRNA levels were comparable between CD and SCA, but highly variable in NFT.

**Expression profile of genes related to intracellular hormone transport**

We finally examined expression profiles of genes related to intracellular hormone transport (Rab3A, syntaxin6, and MARCH2) in ACTH-secreting tumors (CD and SCA) and NFT. Either Rab3A, syntaxin6, or MARCH2 mRNA levels did not differ among the three tumor groups (data not shown).

**Discussion**

The present study using real-time quantitative RT-PCR demonstrates for the first time the differential expression profile of a variety of genes related to POMC transcription, synthesis, processing, and secretion in ACTH-secreting pituitary tumors compared with those in NFT. The LightCycler-based real-time RT-PCR protocol used in this study is considered to be more accurate than conventional techniques because the quantified copy numbers of any given transcripts are normalized with endogenous internal control (GAPDH). The present study clearly showed that ACTH-secreting pituitary tumors causing overt CD expressed far greater (136-fold) POMC mRNA than NFT did and that POMC gene expression in SCA was fivefold greater than that in NFT.

NeuroD1, a basic helix-loop-helix transcription factor, in synergy with other transcription factor Ptx1, is involved in corticotroph-specific transcription of POMC gene and corticotroph cell differentiation (5). It has been reported that NeuroD1 mRNA was expressed in all 3 ACTH-secreting tumors as well as 6 out of 8 NFT by conventional RT-PCR, and NeuroD1 protein was detected.
in all 10 ACTH-secreting pituitary tumors as well as in 14 out of 20 NFT by immunohistochemical study (6), suggesting the important role of NeuroD1 in the functional expression and the differentiation of ACTH-secreting pituitary tumors. In contrast to those of a previous study (6), using small numbers of tumor samples and semiquantitative analyses, our data obtained from more cases with CD and SCA using more accurate and quantitative analysis by real-time RT-PCR clearly showed that ACTH-secreting pituitary tumors causing overt CD expressed far less NeuroD1 mRNA than did NFT and SCA. Thus, our data indicate that NeuroD1 is not sufficient per se to induce the transcription of POMC gene and the development of ACTH-secreting pituitary tumors.

Tpit, a member of transcription factors of the T-box family (7), plays a key role in the differentiation of corticotroph lineage (8). It has been shown that Tpit mRNA was detected and coexpressed with POMC mRNA in three ACTH-secreting pituitary tumors causing CD and one SCA by in situ hybridization study, while Tpit immunoreactivities were detected in 22 out of 26 (85%) ACTH-secreting pituitary tumors, whereas Tpit mRNA was not detected in other type of pituitary tumors (9). Our study is consistent with those of a previous study (9), but further extends the idea that Tpit gene is expressed most abundantly in ACTH-secreting pituitary tumors causing overt CD and more in SCA than in NFT. Thus, our data lend credence to the notion that NeuroD1 is not sufficient per se to induce the transcription of POMC gene and the development of ACTH-secreting pituitary tumors.

CRHR and V1bR, two specific receptors for potent ACTH secretagogues, CRH, and AVP respectively, have been reported to be overexpressed in ACTH-secreting pituitary tumors causing CD (10). Our data are consistent with those of previous studies, lending credence to the contention that patients with CD show hyperresponsiveness of ACTH release to CRH and vasopressin in vivo as well as in vitro (11–13). The present study, however, showed differential gene expression of CRHR and V1bR in SCA; increased V1bR and decreased CRHR mRNA levels. The increased V1bR gene expression in SCA raises the possibility that SCA patients may show responsiveness of ACTH release to vasopressin. Alternatively, the increased V1bR gene expression in SCA may be related to its tumor growth because vasopressin can also activate cAMP formation and phosphorylation of MAP kinases to induce mitogenic effects in cell lines overexpressing human V1bR (14). The decreased CRHR gene expression in SCA, on the other hand, may explain normal and/or subnormal ACTH secretion in most SCA patients (2). Taken together, it appears that there exists differential gene expression profiles of not only POMC and its processing enzymes (PC1/3 and PC3), but also of two major ACTH secretagogue receptors (CRHR and V1bR) between ACTH-secreting pituitary tumors causing CD and SCA.

Both PC1/3 and PC2 are involved in the post-translational proteolytic processing of polypeptide hormones in endocrine tissues, including pancreatic islets and pituitary glands. PC1/3 is a cleaving enzyme responsible for the post-translational processing of POMC into mature ACTH (1–39) in corticotrophs of the anterior pituitary, while PC2 is responsible for the proteolytic processing of mature ACTH (1–39) into α-melanocyte stimulating hormone (α-MSH) and its C-terminal fragment, termed corticotropin-like
intermediate lobe peptide, in the intermediate lobe of the pituitary gland (15, 16). It has been shown that both PC1/3 and PC2 mRNA are expressed in ACTH-secreting pituitary tumors and NFT by conventional RT-PCR (17), and that immunoreactivities of both PC1/3 and PC2 are detected in the normal pituitary gland by immunohistochemical study, while immunoreactivity for PC1/3 is more abundant in ACTH-secreting pituitary tumors causing CD (15, 16, 18). However, PC1/3 expression in SCA by immunohistochemical study has shown conflicting results; negative immunoreactive PC1/3 in one case (19) versus positive immunoreactive PC1/3 in four cases (20, 21).

Our data clearly showed that ACTH-secreting pituitary tumors causing overt CD expressed far greater (136-fold) POMC mRNA associated with threefold more PC1/3 and 33-fold less PC2 mRNA expression than did NFT. The present results of the concomitant enhanced expressions of POMC and PC1/3 genes accompanied by decreased PC2 gene expression in ACTH-secreting pituitary tumors are consistent with accelerated processing of POMC into mature ACTH(1-39), thus causing overt CD. By contrast, our study showed that POMC gene expression in SCA was higher than that in NFT, but far less than that in CD, and that PC1/3 and PC2 gene expressions were concomitantly decreased in SCA. Such differential gene expression of increased POMC with decreased PC1/3 and PC2 in SCA may lead to impaired processing of less bioactive POMC and/or proACTH into mature ACTH(1-39) (22-24), thereby partly accounting for silent or subclinical manifestations of Cushing’s syndrome in SCA. However, the molecular mechanism for the concomitant decreased expression of PC1/3 and PC2 in SCA remains undetermined.

Two isoenzymes of 11β-HSD type 1 that converts cortisone (E) to cortisol (F), and type 2 that converts F to E, play important roles in regulating glucocorticoid hormone action in several tissues, including the anterior pituitary where they can modulate the negative feedback mechanism by glucocorticoids. It has been reported that ACTH-secreting pituitary tumors show enhanced 11β-HSD2 gene expression, but suppressed 11β-HSD1 gene expression (25, 26). These data are consistent with the enhanced 11β-HSD2 gene expression in ACTH-secreting pituitary tumors causing CD, but not in SCA or NFT as demonstrated in this study. Therefore, the increased 11β-HSD2 mRNA expression in ACTH-secreting pituitary tumors might in part explain the partial resistance by glucocorticoids to the negative feedback mechanism in CD.

Although alternation of GRz gene expression has been shown in some ACTH-secreting pituitary tumors, but is normal in most cases (27), polymorphisms in the GR gene and the frequent loss of heterozygosity (LOH) at the GR gene locus may account for the glucocorticoid resistance in the negative feedback mechanism (27-29). The present study did not show any change in GRz gene expression in ACTH-secreting pituitary tumors (CD, SCA), suggesting that the involvement of quantitative defects of GRz gene expression in glucocorticoid resistance in ACTH-secreting pituitary tumors seems remote, although the polymorphisms and/or LOH of the GRz gene as well as defect in peripheral GR and/or postreceptor targets remains to be determined.

It has been reported that ANXA1 acts as a paracrine or juxtacrine mediator of the early inhibitory effects of glucocorticoids on ACTH secretion in the rat anterior pituitary (30, 31). However, our data showed variable gene expressions of ANXA1 in NFT when compared with its stable expression in ACTH-secreting pituitary tumors. Thus, the possible involvement of ANXA1 in dysregulation of ACTH secretion in ACTH-secreting pituitary tumors seems unlikely.

Acetylation of histones, which allows unwinding of the local DNA structure and enables RNA polymerase II to enhance gene transcription, is regulated by a balance between histone acetyltransferases and HDACs (32, 33), while GR recruits HDAC2 to the activated gene to switch off transcription (34). Brg1, an ATPase subunit of the SWI/SNF chromatin remodeling complex (35), by interacting with GR allows chromatin remodeling (36). It has been reported that HDAC2 and Brg1 are important for glucocorticoid-induced transrepression of the POMC gene in the negative feedback regulation mechanism, and that immunoreactivities of either HDAC2 or Brg1 were deficient in 17 out of 36 (48%) ACTH-secreting pituitary tumors (37). Our data clearly showed that HDAC2 mRNA expression is consistently and markedly decreased in all ACTH-secreting pituitary tumors causing CD and SCA, although Brg1 mRNA expression did not differ among the three tumor groups. Therefore, the decreased HDAC2 expression rather than Brg1 expression may partly play a more important role in the partial resistance by glucocorticoids to the negative feedback mechanism in CD.

Recently, it has been reported that a variety of synaptic proteins are involved in neuronal membrane traffic. For example, Rab3A and syntaxin which are involved in exocytosis in the secretory pathway in the rat anterior pituitary (38), and immunoreactivities of Rab3A are positive in human pituitary adenoma (39), and MARCH2, a recently identified member of the mammalian E3 ubiquitin ligase family, localize to endosomal vesicles and the plasma membrane, and associate with syntaxin6 (40). Our data showed no apparent differences in mRNA expression of either Rab3A, syntaxin6 or MARCH2 in ACTH-secreting pituitary tumors and NFT (data not shown), suggesting that the alteration of genes related to intracellular hormone transport is not involved in the secretory pathway in ACTH-secreting pituitary tumors.

In conclusion, the present study on the expression profile of a variety of genes related to POMC transcription, synthesis, processing, and secretion in ACTH-secreting pituitary tumors revealed markedly enhanced expression of POMC and Tpit with concomitantly
increased expression of PC1/3, CRHR, and V1bR in ACTH-secreting pituitary tumors could lead to clinically active or overt CD, while increased 11β-HSD2 and decreased HDAC2 expression may partly explain the impaired negative feedback regulation by glucocorticoids in CD. By contrast, only a mildly increased expression of POMC and Tpit associated with reduced PC1/3 and CRHR expression in SCA may lead to production of less ACTH and/or secretion of less corticotropin-releasing hormone (CRH), arginine vasopressin (AVP), CRH plus AVP, and CRH plus metyrapone in patients with Cushing’s disease. 

Acknowledgements

This study was supported in part by Grants-in-Aid from the Ministry of Health, Labor and Welfare, Japan.

References

26 Huizenga NA, de Lange P, Koper JW, Clayton RN, Farrell WE, van der Lely AJ, Brinkmann AO, de Jong FH & Lamberts SW. Human adrenocorticotropic-secretory pituitary adenomas show...


Received 8 September 2007
Accepted 25 September 2007